Skip Navigation Links
Analysis of Gilead Science
30 Apr 2020 (159 views)

The US stock market jumped on 29 April 2020 on optimism that the the drug remdesivir is tested to be effective in treating the corona virus. It is manufactured by Gilead Science. The US regulator (FDA) is fast tracking the approval of this drug.

Read this article about the study on this drug.

Here are the key financial figures for this company. It has a PE ratio of 18 times and a dividend yield of 3.45%. The price has jumped 33% since 1 Jan. However, it is still not expensive, relative to its potential.

I have decided to buy this share at the current price. (Note - this is sharing my lay person view. I am not giving financial advice.).

Tan Kin Lian
 


Analysis of Gilead Science
[Back] [Print]


The US stock market jumped on 29 April 2020 on optimism that the the drug remdesivir is tested to be effective in treating the corona virus. It is manufactured by Gilead Science. The US regulator (FDA) is fast tracking the approval of this drug.

Read this article about the study on this drug.

Here are the key financial figures for this company. It has a PE ratio of 18 times and a dividend yield of 3.45%. The price has jumped 33% since 1 Jan. However, it is still not expensive, relative to its potential.

I have decided to buy this share at the current price. (Note - this is sharing my lay person view. I am not giving financial advice.).

Tan Kin Lian